RBM10 and lung adenocarcinoma: The survival curve results showed that there were statistically significant differences in the risk of some clinical factors in patients with RBM10 (+) lung adenocarcinoma, including age (p < 0.001), gender (female, p < 0.001; male, p = 0.042), M0 (p < 0.001), N1–3 (p = 0.001), stage I–II (p = 0.050), stage III–IV (p < 0.001), T1–2 (p = 0.002), and T3–4(p = 0.020) (Figure 4I–VI).